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Q Do oral decongestants have a 
clinically significant effect on BP 
in patients with hypertension?
ONLINE
EXCLUSIVE
 It is unclear. Pseudoephedrine 
 causes an average increase of 
1.2 mm Hg in systolic blood pressure (BP) 
in patients with controlled hypertension. 
However, the studies are not adequately 
powered to provide evidence about 
whether this rise in systolic BP is linked 
to patient-oriented outcomes (strength of 
recommendation [SOR]: C, multiple ran-
domized controlled trials [RCTs] support-
ing disease-oriented evidence). Significant 
variations in BP are defined differently 
among studies (TABLE1-7). In addition, we 
do not have data on chronic use of oral de-
congestants; the longest time on medica-
tion in these trials was 4 weeks.
Evidence summary
A meta-analysis of 24 RCTs examined the 
effect of pseudoephedrine on BP and heart 
rate.1 Just 5 of the 24 studies specifically in-
cluded hypertensive patients. In the popu-
lation of patients with hypertension, the 
meta-analysis showed a small (1.2 mm Hg) 
rise in systolic BP with pseudoephedrine that 
was statistically significant (95% confidence 
interval [CI], 0.56-1.84 mm Hg), but the slight 
changes in diastolic BP and heart rate were 
not significant. No patient-oriented out-
comes were measured. 
The highest quality study within this 
group was a randomized, double-blind, 
placebo-controlled crossover study with 
28 patients given sustained-release pseudo-
ephedrine 120 mg twice daily for 72 hours, 
with BP measurements taken at 48 and 
72 hours.2 The study was powered to identify 
an increase in systolic BP of 11 mm Hg, but 
the results showed just a 3.1 mm Hg rise in 
systolic BP at 48 hours (see TABLE1-7 for CI and 
other data). 
In another double-blind, placebo- 
controlled RCT of 29 adults with hyperten-
sion (only 25 were included in the data analy-
sis), there was no significant elevation in BP 
when oral pseudoephedrine was adminis-
tered over the course of 3 days.3 
Across the 5 studies in the meta-analysis, 
immediate-release and sustained-release 
forms of pseudoephedrine were included, 
hypertension was described as controlled but 
definitions of control were not always speci-
fied, and study length varied from 2 hours to 
4 weeks.2-6 Patients on antihypertensive med-
ications were included in some of the stud-
ies; patients who had active cardiovascular 
disease, peripheral vascular disease, and/or 
cerebrovascular disease were excluded. 
One study specifically looked at the ef-
fects of a single dose of pseudoephedrine on 
BP in patients treated with 2 different beta-
blockers and found no significant change 
from baseline, but this study was not pow-
ered to show differences less than 5 mm Hg.6 
The study did show a change of 1 to 2 mm Hg 
in systolic BP, but this was not statistically 
significant.
An absence of information 
on older patients 
There is a paucity of literature on treating 
older adults and medically complex patients 
(eg, those with uncontrolled or secondary 
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causes of hypertension, cerebrovascular dis-
ease, coronary artery disease) with decon-
gestants, as they were excluded in all studies. 
And the available evidence does not include 
reports of adverse events other than changes 
in BP.                    JFP 
TABLE
What effect do oral decongestants have on BP in patients with hypertension?
Study type Intervention Population studied Exclusion criteria Mean change in BP in mm Hg  
(95% CI, P value, SD)
Meta-analysis1 
(n=127)
See studies involving oral PSE outlined below. SBP: 1.2 (0.56 to 1.84; P<.001)
RCT2 (n=28) Oral PSE 
(sustained 
release, bid)
Adults with diet- 
and/or medication-
controlled hyperten-
sion
Active CAD or CVD, Tx with: 
sympathomimetics, alpha- 
adrenergic blockers, or 
MAOIs, secondary HTN,  
pregnancy, glaucoma, known 
BPH
At 48 hours: 
SBP: 3.1 (3.2 to 9.4) 
DBP: 5.5 (-1.9 to 8.9)
At 72 hours: 
SBP: 2.7 (-1.7 to 6.7) 
DBP: 2.5 (-1.7 to 6.7)
RCT3 
(n=25)
Oral PSE 
(immediate 
release, qid)
Adults with medica-
tion-controlled HTN
Diabetes, CVD, PVD, CAD, Tx 
with alpha-blockers or  
combination alpha- and  
beta-blockers
Unknown mean change, 
SBP SD=9.4 (P>.05) 
DBP SD=7.7 (P>.05)
RCT4 
(n=20) 
Oral PSE 
(immediate 
release)
Adults with diet- 
and/or medication-
controlled HTN
Unknown SBP: 2.9 (0.5 to 5.3) 
DBP: 1.1 (-0.9 to 3.1) 
(P<.03 for SBP only)
RCT5 
(n=25)
Oral PSE 
(immediate 
release tid)
Adults with  
medication- 
controlled HTN
CAD, CVD, allergy to medica-
tion, Tx with MAOIs, medical 
noncompliance
SBP: 0 (SD=4.1) 
DBP: -0.5 (SD=2.8) 
(P>.05, SBP and DBP)
RCT6 
(n=29)
Oral PSE 
(immediate 
release, var-
ied doses)
Adults with diet- 
controlled HTN 
(studied after 
administration of 
beta-blockers)
Secondary HTN, cardiac 
disease, PVD, coagulopathy, 
chronic pulmonary disease, 
impaired renal or liver func-
tion, diabetes mellitus, and 
obesity
Insignificant SBP and DBP change 
after placebo, propranolol, and 
atenolol (all P values >.92)
Meta-analysis7 
(In the studies of 
patients with  
hypertension, 
n=78)
Oral PPA* Adults with HTN 
(subset of meta-
analysis)
Varied between study groups SBP: 3.16 (-2.23 to 8.55) 
DBP: 2.16 (-0.98 to 5.31)
bid, 2 times daily; BP, blood pressure; BPH, benign prostatic hyperplasia; CAD, coronary artery disease; CI, confidence interval; CVD, cerebrovascular disease; DBP, 
diastolic blood pressure; HTN, hypertension; MAOIs, monoamine oxidase inhibitors; PPA, phenylpropanolamine; PSE, pseudoephedrine; PVD, peripheral vascular 
disease; qid, 4 times daily; RCT, randomized controlled trial; SBP, systolic blood pressure; SD, standard deviation; tid, 3 times daily.
*No longer available in the United States. 
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